Table 1.

Patient characteristics

^*folinic acid, 5-fluorouracil and oxaliplatin, ^†comorbidities included diabetes (n=52), hypertension and/or history of cardiovascular disease (n=23), viral hepatitis B (n=11) and history of other malignancies (n=2), ^‡Eastern Cooperative Oncology Group, ^§in palliative setting, 23 patients were treated with bevacizumab concomitantly with FOLFOX or XELOX, ^∥capecitabine and oxaliplatin.